KRAS G12C-mutant non-small-cell lung cancer: biology, developmental therapeutics, and molecular testing

KRAS mutation is the most typical oncogenic driver in superior non-small cell lung most cancers (NSCLC), occurring in roughly 30% of lung adenocarcinomas. Over 80% of oncogenic KRAS mutations happen at codon 12 the place the glycine residue is substituted by completely different amino acids, resulting in genomic heterogeneity of KRAS-mutant tumors. The KRAS glycine-to-cysteine…

Read More